Cargando…

Therapeutic strategies in epithelial ovarian cancer

Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Ayako, Ueda, Yutaka, Naka, Tetsuji, Enomoto, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309949/
https://www.ncbi.nlm.nih.gov/pubmed/22330607
http://dx.doi.org/10.1186/1756-9966-31-14
_version_ 1782227586009530368
author Kim, Ayako
Ueda, Yutaka
Naka, Tetsuji
Enomoto, Takayuki
author_facet Kim, Ayako
Ueda, Yutaka
Naka, Tetsuji
Enomoto, Takayuki
author_sort Kim, Ayako
collection PubMed
description Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway.
format Online
Article
Text
id pubmed-3309949
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33099492012-03-23 Therapeutic strategies in epithelial ovarian cancer Kim, Ayako Ueda, Yutaka Naka, Tetsuji Enomoto, Takayuki J Exp Clin Cancer Res Review Ovarian cancer is the most lethal gynecologic malignancy. It appears that the vast majority of what seem to be primary epithelial ovarian and primary peritoneal carcinomas is, in fact, secondary from the fimbria, the most distal part of the fallopian tube. Treatment of epithelial ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum. Although clear cell type is categorized in indolent type, it is known to show relatively strong resistance to carboplatin and paclitaxel regimen and thus poor prognosis compared to serous adenocarcinoma, especially in advanced stages. Irinotecan plus cisplatin therapy may effective for the clear cell adenocarcinoma. The larger expectation for improved prognosis in ovarian carcinoma is related to the use of the new biological agents. One of the most investigated and promising molecular targeted drugs in ovarian cancer is bevacizumab, a monoclonal antibody directed against VEGF. PARP inhibitor is another one. A few recent studies demonstrated positive results of bevacizumab on progression-free survival in ovarian cancer patients, however, investigation of molecular targeting drugs in patients with ovarian cancer are still underway. BioMed Central 2012-02-13 /pmc/articles/PMC3309949/ /pubmed/22330607 http://dx.doi.org/10.1186/1756-9966-31-14 Text en Copyright ©2012 Kim et al; BioMed Central Ltd.2012 http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
spellingShingle Review
Kim, Ayako
Ueda, Yutaka
Naka, Tetsuji
Enomoto, Takayuki
Therapeutic strategies in epithelial ovarian cancer
title Therapeutic strategies in epithelial ovarian cancer
title_full Therapeutic strategies in epithelial ovarian cancer
title_fullStr Therapeutic strategies in epithelial ovarian cancer
title_full_unstemmed Therapeutic strategies in epithelial ovarian cancer
title_short Therapeutic strategies in epithelial ovarian cancer
title_sort therapeutic strategies in epithelial ovarian cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309949/
https://www.ncbi.nlm.nih.gov/pubmed/22330607
http://dx.doi.org/10.1186/1756-9966-31-14
work_keys_str_mv AT kimayako therapeuticstrategiesinepithelialovariancancer
AT uedayutaka therapeuticstrategiesinepithelialovariancancer
AT nakatetsuji therapeuticstrategiesinepithelialovariancancer
AT enomototakayuki therapeuticstrategiesinepithelialovariancancer